Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
CVKD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.70 - $22.90
Previous CloseN/A
Volume16.20K
Average Volume (3M)31.93K
Market Cap
$20.32M
Enterprise Value$25.17M
Total Cash (Recent Filing)$7.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 07, 2025EPS Estimate
-1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding1,966,675
10 Day Avg. Volume22,995
30 Day Avg. Volume31,926
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.56K
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$32.00Price Target Upside193.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe agreement brings Abbott’s extensive development experience and clinical network to the TECH-LVAD trial.
PartnershipsCadrenal announced a development agreement with Abbott to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD.
Supply ChainCadrenal completed the technical transfer and manufacturing transition of tecarfarin’s drug substance from an Asia-based CDMO to one in the U.S., which should help support its clinical and regulatory development strategy and improve supply chain security.
Bears Say
Financial PositionCadrenal ended the quarter with $7.3 million, which is highlighted as a significant concern, as additional funding will be necessary to support ongoing operations.
Funding RisksNext steps involve submitting a full study design synopsis and additional justification for key design elements to the FDA, with the anticipation that the Phase 3 TECH-LVAD trial could begin by YE25, assuming necessary funding is secured.
Regulatory ChallengesThe FDA meeting led to an agreement that demonstrating superiority in the trial would not be feasible, leading to alignment on a non-inferiority design instead.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $5.70 and its highest was $22.90 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $20.32M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 07, 2025 which is tomorrow.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 08, 2025. The company reported -$2.09 earnings per share for the quarter, beating the consensus estimate of -$2.15 by $0.06.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.78.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 1,966,675 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$2.09 in its last earnings report, beating expectations of -$2.15. Following the earnings report the stock price went down -4.791%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
Cadrenal Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (193.58% Upside)
$32.00 (193.58% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.86%
12-Months-Change
Fundamentals
Return on Equity
-208.59%
Trailing 12-Months
Asset Growth
12.84%
Trailing 12-Months
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. (CVKD) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cardiovascular diseases. The company is dedicated to addressing unmet medical needs by advancing innovative solutions that improve patient outcomes. Its core product offerings typically revolve around proprietary drug formulations and therapeutic interventions aimed at treating specific cardiac-related conditions.
CVKD Stock 12 Month Forecast
Average Price Target
$32.00
▲(193.58% Upside)